Want to see AU:PAR full AI Analyst Report?
Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.24
▲(7.27% Upside)
Action:Reiterated
Date:09/12/26
The score is held down primarily by weak financial performance—persistent large losses, negative cash generation, and a notable 2026 increase in leverage and reduced equity. Technicals provide partial offset with a short-to-medium-term uptrend and positive MACD, but overbought signals raise pullback risk. Valuation remains challenged due to negative earnings and no stated dividend yield.
Positive Factors
Revenue Growth
The reported revenue growth indicates that the company has expanded its top line despite its small and volatile revenue base. If this growth can be sustained, it could improve operating scale, support broader commercial adoption, and provide a foundation for future margin improvement.
Negative Factors
Persistent Unprofitability
Persistent losses and recurring negative gross profit show that the business has not established a stable, profitable operating model. Losses that remain large relative to revenue can consume capital, limit reinvestment capacity, and make future profitability dependent on significant improvement in scale or cost structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The reported revenue growth indicates that the company has expanded its top line despite its small and volatile revenue base. If this growth can be sustained, it could improve operating scale, support broader commercial adoption, and provide a foundation for future margin improvement.
Read all positive factors
Paradigm Biopharmaceuticals (PAR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$153.48M
Dividend YieldN/A
Average Volume (3M)885.05K
Price to Earnings (P/E)―
Beta (1Y)2.40
Revenue Growth53.78%
EPS Growth-206.24%
CountryAU
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding626,433,350
10 Day Avg. Volume0
30 Day Avg. Volume885,052
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)17.59
Price to Sales (P/S)761.77
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside90.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)N/A
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Company Description
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium,...
How the Company Makes Money
null...
Paradigm Biopharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 80.15K | 52.12K | 65.80K | 46.76K | 79.22K |
| Gross Profit | -82.37K | -19.89K | 56.81K | -18.83K | -64.53K |
| EBITDA | -60.96M | -25.25M | -64.54M | -59.06M | -46.82M |
| Net Income | -56.33M | -18.77M | -58.65M | -51.91M | -39.25M |
Balance Sheet | |||||
| Total Assets | 30.55M | 24.57M | 27.39M | 67.07M | 50.69M |
| Cash, Cash Equivalents and Short-Term Investments | 15.44M | 16.82M | 17.87M | 56.38M | 39.72M |
| Total Debt | 7.51M | 5.48K | 239.33K | 341.67K | 616.67K |
| Total Liabilities | 27.08M | 3.39M | 3.58M | 13.39M | 8.38M |
| Stockholders Equity | 3.47M | 21.18M | 23.81M | 53.68M | 42.31M |
Cash Flow | |||||
| Free Cash Flow | -43.69M | -15.99M | -65.94M | -45.19M | -32.21M |
| Operating Cash Flow | -43.69M | -15.99M | -65.94M | -45.19M | -32.21M |
| Investing Cash Flow | -552.32K | 46.20K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 43.69M | 14.99M | 28.18M | 62.53M | 70.12K |
Paradigm Biopharmaceuticals Technical Analysis
Positive
0.22
Price Trends
0.23
Positive
0.20
Positive
0.22
Positive
Market Momentum
<0.01
Positive
56.01
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PAR, the sentiment is Positive. The current price of 0.22 is below the 20-day moving average (MA) of 0.25, below the 50-day MA of 0.23, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.01 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PAR.
Paradigm Biopharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% | |
47 Neutral | AU$123.08M | -4.02 | 362.74% | ― | -22.13% | -108.82% | |
45 Neutral | AU$108.55M | -6.76 | 84.67% | ― | ― | 42.51% | |
44 Neutral | AU$166.59M | -9.79 | -103.42% | ― | ― | 5.88% | |
44 Neutral | AU$33.14M | -0.39 | -118.74% | ― | 499.47% | 31.20% | |
41 Neutral | AU$41.06M | -4.85 | -18.71% | ― | ― | 21.23% |
* Healthcare Sector Average
AU:PAR
Paradigm Biopharmaceuticals
0.25
-0.20
-44.94%
AU:ATX
Amplia Therapeutics
0.08
-0.05
-40.00%
AU:ACW
Actinogen Medical
0.05
0.01
34.29%
AU:DXB
Dimerix Limited
0.21
-0.32
-60.58%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.13
-91.03%
AU:RCE
Recce Pharmaceuticals Ltd.
0.35
-0.07
-16.87%
Paradigm Biopharmaceuticals Corporate Events
Paradigm Biopharmaceuticals issues cleansing notice for new convertible notes tranche
Sep 11, 2026
Paradigm Biopharmaceuticals has issued a cleansing notice covering a new tranche of US$2 million in convertible notes, known as the September 2026 Notes, under its existing funding agreement with Obsidian Global GP LLC. This latest drawdown lifts ...
Paradigm Biopharmaceuticals Issues 2 Million Unquoted Convertible Notes
Sep 11, 2026
Paradigm Biopharmaceuticals Limited has notified the market of the issuance of 2,000,000 unquoted convertible notes under its ASX Appendix 3G obligations. The notes, which are not intended to be quoted on the ASX, were issued on 11 September 2026 ...
Paradigm Secures Further Funding as Knee Osteoarthritis Phase 3 Trial Fully Enrolled
Sep 11, 2026
Paradigm Biopharmaceuticals has strengthened its balance sheet by drawing down the remaining US$2 million from Tranche 4 of its US$27 million Convertible Note Facility with Obsidian Global Partners, lifting available working capital to support its...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 18.9 Million New Shares
Sep 11, 2026
Paradigm Biopharmaceuticals Limited, an ASX-listed biopharmaceutical company trading under the ticker PAR, develops and commercializes therapeutic products in the healthcare and biotechnology sector, with its capital structure based on ordinary fu...
Paradigm Biopharmaceuticals to Brief Investors on Late-Stage Osteoarthritis Drug
Sep 2, 2026
Paradigm Biopharmaceuticals has scheduled an investor lunch briefing in Melbourne on 23 September 2026, where senior management will present an update on the development of Zilosul, its injectable pentosan polysulfate sodium candidate for knee ost...
Paradigm Biopharmaceuticals lodges updated ASX corporate governance disclosures
Aug 28, 2026
Paradigm Biopharmaceuticals has lodged its annual corporate governance materials with the ASX for the year ended 30 June 2026, confirming that its up‑to‑date corporate governance statement is available on the company’s website. T...
Paradigm Biopharmaceuticals’ Loss Widens Despite Revenue Growth
Aug 28, 2026
Paradigm Biopharmaceuticals reported revenue from continuing activities of $8.1 million for the year ended 30 June 2026, a 14.4% increase on the prior period, but posted a significantly larger net loss attributable to members of $56.3 million, mor...
Paradigm Biopharmaceuticals Expands ASX-Listed Share Base
Aug 25, 2026
Paradigm Biopharmaceuticals Limited has applied for quotation of 7,658,797 new ordinary fully paid shares on the ASX, with an issue date of August 25, 2026. The new securities arise from the exercise or conversion of existing options or other conv...
Paradigm’s Phase 3 Osteoarthritis Trial Clears 80% Safety Review, Interim Analysis on Track
Aug 13, 2026
Paradigm Biopharmaceuticals reported that an independent Data Safety Monitoring Board has completed the planned 80% safety review of participants in its pivotal Phase 3 PARA_OA_012 trial in knee osteoarthritis without recommending any changes. Thi...
Paradigm Biopharmaceuticals Seeks Quotation for Over 5.2 Million New ASX Shares
Jul 30, 2026
Paradigm Biopharmaceuticals Limited has applied for the quotation of 5,209,080 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of July 30, 2026. The additional securities, arising from the exercise or conve...
Paradigm Biopharmaceuticals Cancels Shares Under Employee Scheme Buy-Back
Jul 26, 2026
Paradigm Biopharmaceuticals has updated the market on changes to its issued capital, notifying the cessation of 300,000 ordinary fully paid shares. The shares were cancelled as a result of an employee share scheme buy-back, reflecting routine capi...
Paradigm gains $5.75m tax-related cash boost to fund Phase 3 osteoarthritis program
Jul 21, 2026
Paradigm Biopharmaceuticals has received a combined $5.75 million in cash through Australia’s Research Development Tax Incentive for FY25 and an amended FY23 income tax refund, bolstering its balance sheet. The additional funding supports t...
Paradigm Biopharmaceuticals issues cleansing notice for latest US$3m convertible notes
Jul 13, 2026
Paradigm Biopharmaceuticals has issued a cleansing notice covering a new tranche of US$3 million in convertible notes, termed the July 2026 Notes, under its existing convertible securities and share placement agreement with Obsidian Global GP LLC....
Paradigm Biopharmaceuticals Issues 3 Million Unquoted Convertible Notes
Jul 13, 2026
Paradigm Biopharmaceuticals has notified the market of the issuance of 3,000,000 unquoted convertible notes under the ASX Appendix 3G framework. The notes, recorded with the security code PARAAD and issued on July 13, 2026, form part of a previous...
Paradigm Secures Fresh Funds to Advance Phase 3 Knee Osteoarthritis Trial
Jul 13, 2026
Paradigm Biopharmaceuticals has drawn down Tranche 4 of its US$27 million convertible note facility with Obsidian Global Partners, securing an additional US$3 million in working capital. The funds will support the ongoing global Phase 3 clinical t...
Paradigm Biopharmaceuticals updates market on director’s shareholding change
Jul 1, 2026
Paradigm Biopharmaceuticals has disclosed a change in director Paul Rennie’s relevant interests in the company’s securities, as required under ASX listing rules. The notice details his mix of direct and indirect holdings, including ful...
Paradigm Biopharmaceuticals Cancels 939,500 Lapsed Performance Rights
Jun 29, 2026
Paradigm Biopharmaceuticals has reported the lapse of 939,500 performance rights, identified under the ASX security code PARAAC, after the conditions attached to these rights were not met or became incapable of being satisfied. The cessation of th...
Paradigm Biopharmaceuticals Cancels Shares Under Employee Scheme Buy-Back
Jun 29, 2026
Paradigm Biopharmaceuticals has cancelled 1,795,000 ordinary fully paid shares as part of an employee share scheme buy-back, effective June 29, 2026. The reduction in issued capital reflects the company’s ongoing management of its equity str...
Paradigm Biopharmaceuticals Updates Director Matthew Fry’s Option Holdings
Jun 18, 2026
Paradigm Biopharmaceuticals has disclosed a change in the indirect interests of director Matthew Fry, who has been issued 176,470 listed options at an exercise price of $0.2375, expiring on December 1, 2026, under an options offer. Following this ...
Paradigm Biopharmaceuticals updates market on director Paul Rennie’s expanded option holdings
Jun 18, 2026
Paradigm Biopharmaceuticals has reported a change in the interests of director Paul Rennie, reflecting adjustments across his direct and indirect holdings in the company’s securities. The disclosure details his mix of fully paid ordinary sha...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Over 10 Million New Shares
Jun 18, 2026
Paradigm Biopharmaceuticals has applied for the quotation of 10,139,313 new ordinary fully paid shares on the Australian Securities Exchange. The newly issued securities, dated June 18, 2026, expand the company’s quoted share capital, which ...
Paradigm Biopharmaceuticals’ Top 20 Option Holders Control Majority of PAROPTWC Register
Jun 17, 2026
Paradigm Biopharmaceuticals has released an updated top holders report for its listed options expiring 1 December 2026, priced at $0.2375, revealing that the top 20 holders control 57.78% of the 117,069,101 options on issue. Major custodians and n...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 117 Million New Options
Jun 17, 2026
Paradigm Biopharmaceuticals has applied to the ASX for quotation of a new class of options, expanding its listed securities and broadening its capital structure. The company plans to list 117,069,101 options expiring on 1 December 2026 or 20 busin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.